Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb
Lower-limb ischemia is a major health problem. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Novel therapeutic approaches include the intramuscular use of autologous bone marrow cells (BMCs). Because tissue ischemia is associated with an overwhelming generation of oxygen radicals and negative effects due to perturbed shear-stress, metabolic intervention with antioxidants and l-arginine could potentially induce beneficial effects beyond those achieved by BMCs. The protective effect of autologous BMCs and vascular protection by metabolic cotreatment (1.0% vitamin E added to the chow and 0.05% vitamin C and 6% l-arginine added to the drinking water) were examined in ischemia-induced angiogenesis in the mouse hindlimb, a model of extensive acute peripheral arterial occlusion. i.v. BMC therapy improved blood flow and increased capillary densities and expression of Ki-67, a proliferation-associated protein. This beneficial effect was amplified by metabolic cotreatment, an intervention inducing vascular protection, at least in part, through the nitric oxide pathway, reduction of systemic oxidative stress, and macrophage activation. Therefore, although a cautious approach is mandatory when experimental findings are extended to human diseases, autologous BMCs together with metabolic intervention could be an effective clinical treatment for peripheral arterial disease.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 102(2005), 47 vom: 22. Nov., Seite 17202-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Napoli, Claudio [VerfasserIn] |
|---|
| Themen: |
94ZLA3W45F |
|---|
| Anmerkungen: |
Date Completed 12.01.2006 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM158923235 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM158923235 | ||
| 003 | DE-627 | ||
| 005 | 20231223083128.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0530.xml |
| 035 | |a (DE-627)NLM158923235 | ||
| 035 | |a (NLM)16286655 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Napoli, Claudio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2006 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Lower-limb ischemia is a major health problem. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Novel therapeutic approaches include the intramuscular use of autologous bone marrow cells (BMCs). Because tissue ischemia is associated with an overwhelming generation of oxygen radicals and negative effects due to perturbed shear-stress, metabolic intervention with antioxidants and l-arginine could potentially induce beneficial effects beyond those achieved by BMCs. The protective effect of autologous BMCs and vascular protection by metabolic cotreatment (1.0% vitamin E added to the chow and 0.05% vitamin C and 6% l-arginine added to the drinking water) were examined in ischemia-induced angiogenesis in the mouse hindlimb, a model of extensive acute peripheral arterial occlusion. i.v. BMC therapy improved blood flow and increased capillary densities and expression of Ki-67, a proliferation-associated protein. This beneficial effect was amplified by metabolic cotreatment, an intervention inducing vascular protection, at least in part, through the nitric oxide pathway, reduction of systemic oxidative stress, and macrophage activation. Therefore, although a cautious approach is mandatory when experimental findings are extended to human diseases, autologous BMCs together with metabolic intervention could be an effective clinical treatment for peripheral arterial disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Nitrates |2 NLM | |
| 650 | 7 | |a Nitrites |2 NLM | |
| 650 | 7 | |a Arginine |2 NLM | |
| 650 | 7 | |a 94ZLA3W45F |2 NLM | |
| 700 | 1 | |a Williams-Ignarro, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a de Nigris, Filomena |e verfasserin |4 aut | |
| 700 | 1 | |a de Rosa, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Lerman, Lilach O |e verfasserin |4 aut | |
| 700 | 1 | |a Farzati, Bartolomeo |e verfasserin |4 aut | |
| 700 | 1 | |a Matarazzo, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Sica, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Botti, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Fiore, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Byrns, Russell E |e verfasserin |4 aut | |
| 700 | 1 | |a Sumi, Daigo |e verfasserin |4 aut | |
| 700 | 1 | |a Sica, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Ignarro, Louis J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 102(2005), 47 vom: 22. Nov., Seite 17202-6 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2005 |g number:47 |g day:22 |g month:11 |g pages:17202-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2005 |e 47 |b 22 |c 11 |h 17202-6 | ||